Fuji Pharma Of Japan To Buy Control Of Thai Contract Drug Maker OLIC
This article was originally published in PharmAsia News
Executive Summary
Japan’s Fuji Pharma plans to acquire OLIC, Thailand’s largest contract pharmaceutical maker, for just over $54 million, giving the Japanese firm total control.
Japan’s Fuji Pharma plans to acquire OLIC, Thailand’s largest contract pharmaceutical maker, for just over $54 million, giving the Japanese firm total control. The two firms, which expect to close the merger deal in October, have been business partners for several years. Fuji President and CEO Hirofumi Imai said the deal is designed to give his firm a competitive edge in global pharmaceutical competition. Fuji also gets access to OLIC’s large client base that includes major drug makers in Europe, the U.S., Japan and other parts of the globe. (Click here for more
)
“Japan’s Fuji Pharma Set To Take 99.91% In Kingdom’s Top Drug-Maker OLIC” – The Nation (Thailand) (8/7/2012)